1221413-93-9

Basic information

• Product Name: 4-([1,1'-biphenyl]-4-ylmethoxy)benzaldehyde
• Synonyms: 4-([1,1'-biphenyl]-4-ylmethoxy)benzaldehyde
• CAS NO: 1221413-93-9
• Molecular Weight: 288.346
• Mol File: 1221413-93-9.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 4-([1,1'-biphenyl]-4-ylmethoxy)benzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4-([1,1'-biphenyl]-4-ylmethoxy)benzaldehyde(1221413-93-9)
• EPA Substance Registry System: 4-([1,1'-biphenyl]-4-ylmethoxy)benzaldehyde(1221413-93-9)

Safety Data

• Hazardous Substances Data: 1221413-93-9(Hazardous Substances Data)

Upstream product

• 1667-11-4 biphenyl-4-methylchloride 
• 123-08-0 4-hydroxy-benzaldehyde 
• 3597-91-9 biphenyl-4-yl methanol 
• 98-80-6 phenylboronic acid 

Downstream Products

• 1221413-81-5 5-(4-(biphenyl-4-ylmethoxy)benzylidene)thiazolidine-2,4-dione 

Relevant articles and documents

Disruptor of telomeric silencing 1-like (DOT1L): disclosing a new class of non-nucleoside inhibitors by means of ligand-based and structure-based approaches

Abstract: Chemical inhibition of chromatin-mediated signaling involved proteins is an established strategy to drive expression networks and alter disease progression. Protein methyltransferases are among the most studied proteins in epigenetics and, in particular, disruptor of telomeric silencing 1-like (DOT1L) lysine methyltransferase plays a key role in MLL-rearranged acute leukemia Selective inhibition of DOT1L is an established attractive strategy to breakdown aberrant H3K79 methylation and thus overexpression of leukemia genes, and leukemogenesis. Although numerous DOT1L inhibitors have been several structural data published no pronounced computational efforts have been yet reported. In these studies a first tentative of multi-stage and LB/SB combined approach is reported in order to maximize the use of available data. Using co-crystallized ligand/DOT1L complexes, predictive 3-D QSAR and COMBINE models were built through a python implementation of previously reported methodologies. The models, validated by either modeled or experimental external test sets, proved to have good predictive abilities. The application of these models to an internal library led to the selection of two unreported compounds that were found able to inhibit DOT1L at micromolar level. To the best of our knowledge this is the first report of quantitative LB and SB DOT1L inhibitors models and their application to disclose new potential epigenetic modulators. Graphical Abstract: [Figure not available: see fulltext.].

NOVEL THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF

The present invention relates to novel thiazolidinedione derivatives expressed by the following formula (I) and the uses thereof. More specifically, the present invention relates to novel thiazolidinedione derivatives expressed by the following formula (I) and a pharmaceutical composition comprising the same. The novel thiazolidinedione derivatives of formula (I) according to the present invention can be effectively used for the prevention or treatment of cardiovascular disease, gastrointestinal disease and renal disease by inhibiting the activity of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) that decomposes prostaglandins as well as useful for the prevention of hair loss and the stimulation of hair growth, and osteogenic stimulation and wound healing.